MALAT1 and myocardial infarction: In the present study, using a murine permanent MI model involving the administration of SSEA1+-hCVPC-secreted EVs during AMI, combining in vivo and in vitro analysis, we investigated (i) whether hCVPC-EVs improve infarct healing; (ii) whether hCVPC-EVs contain lncRNA candidates benefiting cardiac protection; and (iii) what the miRNA target of hCVPC-EV-contained lncRNA MALAT1 confers the protection of MALAT1 in cardiomyocyte survival and angiogenesis.